Skip to main content

Table 7 Clinical factors and genotypes influencing survival in multivariate analyses

From: Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker

  TTP OS
  HR (95%CI) p-value HR (95%CI) p-value
TS 6-bp deletion in 3'UTR 0.561 (0.331–0.950) 0.032 0.553 (0.285–1.072) 0.079
XPD-Arg156Arg 0.705 (0.407–1.220) 0.210 0.923 (0.456–1.867) 0.823
XPD-Asp312Asn 1.956 (0.902–4.240) 0.089 0.802 (0.281–2.286) 0.679
Performance (ECOG 0–1 vs. 2) 1.973 (1.034–3.762) 0.073 1.638 (0.816–3.288) 0.165
\